Genomic and transcriptomic characterization of papillary microcarcinomas with lateral neck lymph node metastases.
暂无分享,去创建一个
N. Socci | V. Seshan | A. Viale | M. Berger | M. Gonen | N. Camacho | J. Fagin | R. Ghossein | Y. Şenbabaoğlu | R. Tuttle | J. Knauf | N. Bouvier | Dilmi Perera | Juan Li | B. Untch | L. Boucai | Niedzica Camacho | Laura Boucai
[1] V. Seshan,et al. Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. , 2018, Cancer cell.
[2] E. Sokol,et al. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers , 2018, Clinical Cancer Research.
[3] T. Giordano. Genomic Hallmarks of Thyroid Neoplasia. , 2018, Annual Review of Pathology.
[4] A. Miyauchi,et al. Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[5] Oscar Lin,et al. Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance , 2017, JAMA otolaryngology-- head & neck surgery.
[6] V. Seshan,et al. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence , 2017, Clinical Cancer Research.
[7] Liang Liu,et al. SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl‑1 pathway. , 2017, International journal of oncology.
[8] P. Soares,et al. The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications , 2017, Current genomics.
[9] Jin Hwa Kim,et al. Clinicopathological Significance of Loss of p27Kip1 Expression in Papillary Thyroid Carcinoma , 2017, The International journal of biological markers.
[10] Marija Milkovic Perisa,et al. Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma , 2017, Oncology letters.
[11] D. Eterović,et al. Cyclin D1, Ret and P27 Expression in Papillary Thyroid Microcarcinoma , 2017, Acta Clinica Croatica.
[12] Yang Liu,et al. Preoperative predictors of lateral neck lymph node metastasis in papillary thyroid microcarcinoma , 2017, Medicine.
[13] J. van Griensven,et al. Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies. , 2016, The New England journal of medicine.
[14] Jee Soo Kim,et al. Routine Level 2b Dissection may be Recommended Only in N1b Papillary Thyroid Carcinoma with Three- or Four-Level Lateral Lymph Node Metastasis , 2016, Annals of Surgical Oncology.
[15] J. Fagin,et al. Biologic and Clinical Perspectives on Thyroid Cancer. , 2016, The New England journal of medicine.
[16] Tae-Min Kim,et al. Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma , 2016, Oncotarget.
[17] Sun Wook Cho,et al. Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers , 2016, PLoS genetics.
[18] J. Shah,et al. An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. , 2016, Thyroid : official journal of the American Thyroid Association.
[19] C. Sander,et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. , 2016, The Journal of clinical investigation.
[20] R. Sihota,et al. Candidate genes involved in the susceptibility of primary open angle glaucoma. , 2016, Gene.
[21] Su-Jin Shin,et al. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status , 2016, Annals of Surgical Oncology.
[22] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[23] Jae Bok Lee,et al. Endoplasmic reticulum aminopeptidase 2 is highly expressed in papillary thyroid microcarcinoma with cervical lymph node metastasis. , 2015, Journal of cancer research and therapeutics.
[24] S. Mane,et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. , 2015, Human molecular genetics.
[25] N. Lu,et al. Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance. , 2015, Asian Pacific journal of cancer prevention : APJCP.
[26] J. Fagin,et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Steven J. M. Jones,et al. Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.
[28] J. Bishop,et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Harrow,et al. Systematic evaluation of spliced alignment programs for RNA-seq data , 2013, Nature Methods.
[30] T. Chan,et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. , 2013, The Journal of clinical endocrinology and metabolism.
[31] L. Larocca,et al. BRAF (V600E) mutation analysis on liquid‐based cytology‐processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma , 2013, Cancer cytopathology.
[32] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .
[33] P. Ladenson,et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. , 2013, JAMA.
[34] N. Socci,et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. , 2013, The Journal of clinical endocrinology and metabolism.
[35] H. Ryu,et al. Histomorphological factors in the risk prediction of lymph node metastasis in papillary thyroid carcinoma , 2013, Histopathology.
[36] D. Rubello,et al. Aggressive Papillary Thyroid Microcarcinoma: Prognostic Factors and Therapeutic Strategy , 2013, Clinical nuclear medicine.
[37] Joanna A Gibson,et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype–phenotype correlation , 2013, Modern Pathology.
[38] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[39] Tao Huang,et al. Multifocality and Total Tumor Diameter Predict Central Neck Lymph Node Metastases in Papillary Thyroid Microcarcinoma , 2013, Annals of Surgical Oncology.
[40] Kyunghwa Han,et al. Preoperative Prediction of Central Lymph Node Metastasis in Thyroid Papillary Microcarcinoma Using Clinicopathologic and Sonographic Features , 2013, World Journal of Surgery.
[41] Xiangqian Zheng,et al. Papillary Microcarcinoma of the Thyroid: Clinical Characteristics and BRAFV600E Mutational Status of 977 Cases , 2013, Annals of Surgical Oncology.
[42] R. Ralhan,et al. Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma , 2012, BMC Cancer.
[43] J. Golmard,et al. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. , 2012, European journal of endocrinology.
[44] Y. Ko,et al. Correlation of lymphatic vessel density and vascular endothelial growth factor with nodal metastasis in papillary thyroid microcarcinoma , 2012, Head & neck.
[45] R. Seethala,et al. A combined molecular‐pathologic score improves risk stratification of thyroid papillary microcarcinoma , 2012, Cancer.
[46] Yon Seon Kim. Patterns and Predictive Factors of Lateral Lymph Node Metastasis in Papillary Thyroid Microcarcinoma , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[47] Yong-xue Zhu,et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. , 2012, The Journal of clinical endocrinology and metabolism.
[48] E. Kebebew,et al. Molecular pathways associated with mortality in papillary thyroid cancer. , 2011, Surgery.
[49] Herb Chen,et al. Should All Papillary Thyroid Microcarcinomas Be Aggressively Treated?: An Analysis of 18,445 Cases , 2011, Annals of surgery.
[50] B. Niederle,et al. Desmoplastic stromal reaction in papillary thyroid microcarcinoma , 2011, Histopathology.
[51] O. Wang,et al. The BRAF Mutation Is Predictive of Aggressive Clinicopathological Characteristics in Papillary Thyroid Microcarcinoma , 2010, Annals of Surgical Oncology.
[52] D. Giordano,et al. Treatment and prognostic factors of papillary thyroid microcarcinoma , 2010, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.
[53] Eun-Kyung Kim,et al. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. , 2009, Radiology.
[54] M. Gao,et al. Analysis of Differential BRAFV600E Mutational Status in High Aggressive Papillary Thyroid Microcarcinoma , 2009, Annals of Surgical Oncology.
[55] T. Sebo,et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. , 2008, Surgery.
[56] L. Braverman,et al. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. , 2008, European journal of endocrinology.
[57] J. Roh,et al. Central Cervical Nodal Metastasis from Papillary Thyroid Microcarcinoma: Pattern and Factors Predictive of Nodal Metastasis , 2008, Annals of Surgical Oncology.
[58] H. Min,et al. S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid , 2008, Modern Pathology.
[59] M. Santoro,et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.
[60] A. Russo,et al. BRAFV600E mutation and p27kip1 expression in papillary carcinomas of the thyroid ≤1 cm and their paired lymph node metastases , 2007 .
[61] Tae Yong Kim,et al. The BRAF mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinoma , 2006, Clinical endocrinology.
[62] E. Pearce,et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. , 2006, The Journal of clinical endocrinology and metabolism.
[63] P. Ladenson,et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.
[64] A. Miyauchi,et al. Papillary Microcarcinomas of the Thyroid with Preoperatively Detectable Lymph Node Metastasis Show Significantly Higher Aggressive Characteristics on Immunohistochemical Examination , 2005, Oncology.
[65] A. Miyauchi,et al. Ultrasonographically and Anatomopathologically Detectable Node Metastases in the Lateral Compartment as Indicators of Worse Relapse-free Survival in Patients with Papillary Thyroid Carcinoma , 2005, World Journal of Surgery.
[66] J. Chan,et al. Papillary microcarcinoma of the thyroid—Prognostic significance of lymph node metastasis and multifocality , 2003, Cancer.
[67] Koichi Ito,et al. Lymph Node Metastasis From 259 Papillary Thyroid Microcarcinomas: Frequency, Pattern of Occurrence and Recurrence, and Optimal Strategy for Neck Dissection , 2003, Annals of surgery.
[68] A. Børglum,et al. Assignment of the human tryptophanyl-tRNA synthetase gene (WARS) to chromosome 14q32.2 --> q32.32. , 1996, Cytogenetics and Cell Genetics.